Table 2.
Group | Number of cases | GDNF (pg.mL−1) | NSE (μg. L−1) | IL-1β (μg. L−1) | MBP (μg. L−1) | ||||
---|---|---|---|---|---|---|---|---|---|
Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment | ||
The control group | 73 | 354.9 ± 38.6 | 522.5 ± 57.3 | 33.4 ± 4.6 | 22.7 ± 3.6 | 51.6 ± 6.5 | 26.3 ± 4.2 | 2.8 ± 0.5 | 2.4 ± 0.4 |
The research group | 75 | 355.2 ± 38.5 | 592.33 ± 62.5 | 33.2 ± 4.5 | 14.3 ± 2.3 | 51.8 ± 6.7 | 18.3 ± 2.6 | 2.8 ± 0.6 | 2.0 ± 0.3 |
T | / | 1.527 | 17.628 | 0.158 | 15.034 | 1.985 | 16.5428 | 0.854 | 14.936 |
P | / | >0.05 | <0.05 | >0.05 | <0.05 | >0.05 | <0.05 | >0.05 | <0.05 |